Compare Eli Lilly And Co (LLY) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Stanley Black & Decker, Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Stanley Black & Decker, Inc. trades at $88.57 (market cap $13.47B). The key difference: Eli Lilly And Co is far larger — about 77.2× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.77%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| LLY | SWK | |
|---|---|---|
Market Cap | $1.04T | $13.47B |
Volume | 3,064,878 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $1.28K | $104.00 |
52-Week Low | $799.57 | $62.12 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $1.09T | $17.63B |
Dividend Yield | 0.59% | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Stanley Black & Decker (SWK) trades at $89.17, up 0.97% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin rising to 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89, while analyst consensus leans neutral with 43% buy ratings and $93 price target.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness and competitive pressures. The stock offers value characteristics with dividend stability but faces execution risks in achieving projected earnings growth. Near-term direction will depend on Q3 2026 results due November 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
